We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

52 hedge funds and large institutions have $8.72M invested in Navidea Biopharmaceuticals Inc. in 2017 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 8 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 8

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

5% less funds holding

Funds holding: 55 → 52 (-3)

14% less capital invested

Capital invested by funds: $10.1M → $8.72M (-$1.37M)

77% less call options, than puts

Call options by funds: $15K | Put options by funds: $66K

Holders
52
Holders Change
-3
Holders Change %
-5.45%
% of All Funds
1.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
15
Reduced
8
Closed
4
Calls
$15K
Puts
$66K
Net Calls
-$51K
Net Calls Change
+$16K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.78M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$144K
3
SIM
Spark Investment Management
New York
+$42K
4
VKH
Virtu KCG Holdings
New York
+$38.5K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$30.4K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$267K
2
HIIFS
Harel Insurance Investments & Financial Services
Israel
-$193K
3
Millennium Management
Millennium Management
New York
-$188K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$154K
5
UBS Group
UBS Group
Switzerland
-$60.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Tudor Investment Corp
26
Tudor Investment Corp
Connecticut
$27K – – –
SWP
27
Stratos Wealth Partners
Ohio
$27K +$1.14K +100 +4%
Wells Fargo
28
Wells Fargo
California
$24K -$5.34K -470 -19%
Commonwealth Equity Services
29
Commonwealth Equity Services
Massachusetts
$20K – – –
Cambridge Investment Research Advisors
30
Cambridge Investment Research Advisors
Iowa
$19K +$2.84K +250 +18%
LFG
31
LifePlan Financial Group
Ohio
$17K – – –
Citadel Advisors
32
Citadel Advisors
Florida
$17K +$16.7K +1,470 New
Bank of America
33
Bank of America
North Carolina
$15K +$45 +4 +0.3%
SIAS
34
Shine Investment Advisory Services
Colorado
$11K +$11.1K +980 New
LA
35
Lynch & Associates
Indiana
$10K – – –
JCM
36
Jacobi Capital Management
Pennsylvania
$10K +$5.68K +500 +100%
RJA
37
Raymond James & Associates
Florida
$9K – – –
Ameriprise
38
Ameriprise
Minnesota
$8K – – –
UBS Group
39
UBS Group
Switzerland
$6K -$60.3K -5,311 -91%
B
40
Bailard
California
$6K – – –
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
$6K – – –
Group One Trading
42
Group One Trading
Illinois
$5K +$4.6K +405 New
IA
43
IFP Advisors
Florida
$3K +$1.7K +150 +150%
AG
44
Advisor Group
Arizona
$2K – – –
CPIG
45
Chicago Partners Investment Group
Illinois
$2K – – –
MFW
46
Mosaic Family Wealth
Missouri
$2K – – –
AC
47
Alexandria Capital
Virginia
$1K – – –
Citigroup
48
Citigroup
New York
$1K – – –
Manulife (Manufacturers Life Insurance)
49
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1K – – –
ASN
50
Advisory Services Network
Georgia
$1K +$568 +50 New
1
2
3

NAVB Hedge Fund Activity: Q1 2017 in Review

52 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q1 2017, worth a combined $8.72M — down 14% from $10.1M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new NAVB positions and 4 closed out — a net gain of 1 holder — while 15 added to existing stakes and 8 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $1.78M. The largest seller was Goldman Sachs, cutting an estimated $267K.

  • 52 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q1 2017, down from 55 in Q4 2016.
  • Funds reported $8.72M of Navidea Biopharmaceuticals Inc. stock for Q1 2017, down 14% quarter-over-quarter.
  • 5 funds opened new Navidea Biopharmaceuticals Inc. positions in Q1 2017 and 4 closed out, a net change of +1 holder.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q1 2017 was BlackRock, an estimated $1.78M added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q1 2017 was Goldman Sachs, an estimated $267K sold.

Based on aggregated 13F filings for Q1 2017.